↓ Skip to main content

For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders

Overview of attention for article published in Progress in Neuro-Psychopharmacology & Biological Psychiatry, March 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (74th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

policy
1 policy source
twitter
6 X users

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
113 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders
Published in
Progress in Neuro-Psychopharmacology & Biological Psychiatry, March 2015
DOI 10.1016/j.pnpbp.2015.03.006
Pubmed ID
Authors

Rebecca J. Henry, Daniel M. Kerr, David P. Finn, Michelle Roche

Abstract

Toll-like receptors (TLRs) mediate the innate immune response to pathogens and are critical in the host defence, homeostasis and response to injury. However, uncontrolled and aberrant TLR activation can elicit potent effects on neurotransmission and neurodegenerative cascades and has been proposed to trigger the onset of certain neurodegenerative disorders and elicit detrimental effects on the progression and outcome of established disease. Over the past decade, there has been increasing evidence demonstrating that the endocannabinoid system can elicit potent modulatory effects on inflammatory processes, with clinical and preclinical evidence demonstrating beneficial effects on disease severity and symptoms in several inflammatory conditions. This review examines the evidence supporting a modulatory effect of endocannabinoids on TLR-mediated immune responses both peripherally and centrally, and the implications for psychiatric disorders such as depression and schizophrenia. CLASSES OF CANNABINOID-BASED PHARMACOLOGICAL AGENTS CITED IN THE REVIEW: Nonselective CB1/CB2 agonists: Δ(9)-THC, HU210, CP55940, WIN55,212-2 Selective CB2 agonists: JWH-015 FAAH inhibitors: URB597, AA-5HT MAGL/ABHD6 inhibitors: JZL184, MJN110, KML129, WWL70 Endocannabinoid reuptake inhibitors: UCM707, OMDM1/2, AM404.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 113 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Germany 1 <1%
Canada 1 <1%
Unknown 109 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 32 28%
Student > Ph. D. Student 16 14%
Researcher 12 11%
Student > Doctoral Student 9 8%
Other 7 6%
Other 20 18%
Unknown 17 15%
Readers by discipline Count As %
Medicine and Dentistry 23 20%
Agricultural and Biological Sciences 22 19%
Neuroscience 12 11%
Biochemistry, Genetics and Molecular Biology 10 9%
Psychology 7 6%
Other 13 12%
Unknown 26 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 February 2017.
All research outputs
#6,443,738
of 25,374,647 outputs
Outputs from Progress in Neuro-Psychopharmacology & Biological Psychiatry
#766
of 2,706 outputs
Outputs of similar age
#73,256
of 291,959 outputs
Outputs of similar age from Progress in Neuro-Psychopharmacology & Biological Psychiatry
#9
of 36 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 2,706 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 291,959 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.